Navigation Links
European Regulatory Agency Accepts Cell Therapeutics, Inc.'s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
Date:4/1/2008

SEATTLE, April 2, 2008 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTA) today announced that the European Medicines Agency (EMEA) has accepted for review CTI's Marketing Authorization Application (MAA) for XYOTAX(TM) (paclitaxel poliglumex, CT-2103) for first-line treatment of patients with non-small cell lung cancer (NSCLC) with ECOG (Eastern Cooperative Oncology Group) performance status 2 (PS2). CTI submitted the MAA at the beginning of March. The validation of the MAA for XYOTAX initiates the marketing approval review process, which generally takes 15 to 18 months. The application is based on advice from the Scientific Advice Working Party, or SAWP, at the EMEA. The EMEA agreed that switching the primary endpoint from superiority to non-inferiority is feasible if the retrospective justification provided in the marketing application is adequate. The discussions with the SAWP focused on using the STELLAR 4 study as primary evidence of non-inferiority and the STELLAR 3 study as supportive of the MAA.

In the STELLAR 4 trial, single-agent XYOTAX resulted in comparable survival to gemcitabine or vinorelbine in first-line patients and, with the exception of neuropathy known to be associated with taxane therapy, demonstrated significant reduction in several clinically meaningful toxicities, such as severe neutropenia and infection, and in the requirement for transfusions and use of hematopoietic growth factor support. In addition to improved tolerability, XYOTAX offered more convenient administration compared to currently used treatments and a reduction in overall utilization of medical resources compared to gemcitabine or vinorelbine.

"CTI looks forward to working with the EMEA as it begins the review
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
2. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
3. European Experts Recommend Pregnant and Nursing Women Take More DHA - Every Day
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
6. Threshold Pharmaceuticals Announces Two Presentations on Glufosfamide at the 2007 European Cancer Conference (ECCO)
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Life Recovery Systems Receives European CE Mark Approval for Its ThermoSuit(R) System
9. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
10. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
11. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... FRANCISCO, Calif. , Aug. 27, 2015 /PRNewswire/ ... therapeutics for the treatment of cancer, today announced ... member of the company,s Board of Directors, has ... led immuno-oncology at Eli Lilly and AstraZeneca, and ... first FDA approved checkpoint inhibitor, at Bristol-Myers Squibb ...
(Date:8/27/2015)... and MENLO PARK, Calif. , ... (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company ... therapies, today announced that it will release its year-end ... 2015 on Friday, September 4, 2015. ... call and live webcast for investors, analysts and other ...
(Date:8/27/2015)... , Aug. 27, 2015  SciClone Pharmaceuticals, Inc. (NASDAQ: ... PhD, Chief Executive Officer, will present a corporate overview and ... in New York City . , ... at 11:30 am ET at the Millennium Broadway Hotel. ... 3:00 pm ET at the St. Regis Hotel. ...
Breaking Medicine Technology:Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 2Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 3DelMar Pharmaceuticals to Announce Fiscal 2015 Year-End Financial Results on September 4, 2015 2DelMar Pharmaceuticals to Announce Fiscal 2015 Year-End Financial Results on September 4, 2015 3SciClone To Present At Two Investor Conferences On September 10, 2015 2
... , NANJING , China ... SCR ), a leading manufacturer and supplier of ... (also known as Endu) in China , announced today ... conference in Beijing ,dedicated to this study. The New ...
... March 18 Jeffrey B. Kindler , ... chairman of the Pharmaceutical Research and Manufacturers of America ... elected were sanofi-aventis Chief Executive Officer Christopher Viehbacher ... and John C. Lechleiter , Ph.D., Chairman, President ...
Cached Medicine Technology:Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study 2Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study 3Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study 4Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study 5Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 2Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 3Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 4Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 5Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 6Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 7Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 8
(Date:8/27/2015)... , ... August 27, 2015 , ... ... instruments available for quantitative PCR (qPCR) in the last decade. New ... and reduced operating costs. On the flipside, where do lab managers, technicians, and ...
(Date:8/27/2015)... ... August 27, 2015 , ... Allegheny General ... just 20 adult-only medical centers in the United States to receive international recognition ... lungs. The Extracorporeal Life Support Organization (ELSO) , an international consortium of ...
(Date:8/27/2015)... , ... August 27, 2015 , ... The Naderi Center ... be offering Kybella, a cutting-edge, noninvasive procedure to improve submental fat. The first ... provides permanent results without surgery. Dr. Kulak is the only Board Certified surgeon ...
(Date:8/27/2015)... R.I. (PRWEB) , ... August 27, 2015 , ... More ... on a road trip. That’s why Amica Insurance is sharing some tips to help ... of America, about 30 million people travel with pets each year. Amica is sharing ...
(Date:8/27/2015)... London, UK (PRWEB) , ... ... ... Ltd and Black Swan Analysis signed a partnership agreement for quality market ... sell research reports elaborated by Black Swan Analysis. , Commenting on the ...
Breaking Medicine News(10 mins):Health News:Douglas Scientific® Webinar Outlines Comparisons of Varied qPCR Instruments 2Health News:Douglas Scientific® Webinar Outlines Comparisons of Varied qPCR Instruments 3Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 2Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 3Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 4Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 2Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 3Health News:Amica Unleashes 5 Tips for Safe Traveling with Pets 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 3
... treatments can be the worst news a cancer patient ... of Missouri-Columbia is working steadfastly to learn why some ... drug cisplatin, in hopes of identifying the particular genes ... as possible. , In a paper published in the ...
... adult suffers a cardiorespiratory arrest the rapid application of ... death in many cases. Nevertheless, defibrillation also has its ... from the moment of the attack, the possibilities of ... to avoid avoidable deaths, more and more easy-to-handle, automatic ...
... RICHMOND, Va., Oct. 2 Filtrona Fibertec, a ... and,manufacturer of custom fluid handling components, celebrated the ... Ningbo, China with a Grand Opening,celebration. (Logo: ... an increase of more than double the size ...
... California, October 2 joimax GmbH, Campbell,CA, is pleased ... Inc. the company is moving to larger premises in ... October 1st, 2007,joimax, Inc. will be located at ... CA 95008 USA "This move reflects the strong ...
... Nutrition Systems, LLC has added over,6,000 menu items ... dining,restaurant chains to http://www.NutritionPedia.com, the only ... find out the,nutritional content of their favorite menu ... dining and buffet style restaurants such as,Applebee,s Neighborhood ...
... Cements Position as Leading ,Single Source, Provider for ... Healthcare Technology Based Mobility ... Inc. (Nasdaq:,IFLG), a leading technology provider of mobile ... today that it has acquired,Healthcare Informatics Associates, Inc. ...
Cached Medicine News:Health News:MU researchers studying model to learn why certain cancers become resistant to drugs 2Health News:Algorithms to reanimate the heart 2Health News:Algorithms to reanimate the heart 3Health News:Filtrona Fibertec Ningbo, China Plant Celebrates Expansion 2Health News:NutritionPedia Adds Nutrition Facts for Over 6,000 Menu Items From 70 Leading Fast-Casual and Family Dining Restaurant Chains 2Health News:InfoLogix Acquires Healthcare Informatics Associates Inc. (HIA); Adds Premier Healthcare Consulting Firm and Systems Integrator 2Health News:InfoLogix Acquires Healthcare Informatics Associates Inc. (HIA); Adds Premier Healthcare Consulting Firm and Systems Integrator 3Health News:InfoLogix Acquires Healthcare Informatics Associates Inc. (HIA); Adds Premier Healthcare Consulting Firm and Systems Integrator 4
New - Color Coded Berman Airways. A simple idea makes size identification easier for you., ,Premium upgrade without a premium price. Color Coded Berman airways are latex-free., ,Plastic. Single use...
Plastic. Economical. Single use. Non-Sterile....
... Portex® Blue Line® uncuffed endotracheal ... or Murphy styles, in standard ... Line® adult and pediatric uncuffed ... implant-tested polyvinyl chloride with a ...
... Portex® Blue Line® uncuffed endotracheal ... or Murphy styles, in standard ... Line® adult and pediatric uncuffed ... implant-tested polyvinyl chloride with a ...
Medicine Products: